BNP Paribas Financial Markets Reduces Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

BNP Paribas Financial Markets lessened its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 10.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 173,480 shares of the company's stock after selling 19,446 shares during the period. BNP Paribas Financial Markets owned 0.24% of Kiniksa Pharmaceuticals worth $3,431,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Franklin Resources Inc. lifted its stake in Kiniksa Pharmaceuticals by 1.7% during the third quarter. Franklin Resources Inc. now owns 67,533 shares of the company's stock valued at $1,798,000 after buying an additional 1,100 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Kiniksa Pharmaceuticals in the third quarter worth $4,997,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company's stock worth $3,947,000 after acquiring an additional 3,673 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth $355,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Kiniksa Pharmaceuticals by 12.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after buying an additional 1,004 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Ross Moat sold 64,035 shares of the business's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $25.21, for a total value of $1,614,322.35. Following the transaction, the insider now directly owns 9,415 shares of the company's stock, valued at approximately $237,352.15. The trade was a 87.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sanj K. Patel sold 2,872 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $27.03, for a total transaction of $77,630.16. Following the sale, the chief executive officer now directly owns 96,674 shares in the company, valued at approximately $2,613,098.22. This trade represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 231,640 shares of company stock worth $5,669,136 in the last quarter. 54.57% of the stock is owned by corporate insiders.

Kiniksa Pharmaceuticals Trading Down 0.7%

KNSA stock traded down $0.20 during mid-day trading on Tuesday, hitting $26.54. The stock had a trading volume of 18,517 shares, compared to its average volume of 482,794. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $17.38 and a 52 week high of $28.56. The firm has a market capitalization of $1.94 billion, a P/E ratio of -189.56 and a beta of 0.07. The firm has a fifty day simple moving average of $22.95 and a 200 day simple moving average of $21.37.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. During the same period last year, the company earned ($0.25) EPS. The firm's revenue was up 72.5% compared to the same quarter last year. As a group, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Wedbush reissued an "outperform" rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Citigroup began coverage on shares of Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price target for the company. Finally, Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $38.80.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.